ARS Pharmaceuticals, Inc. (SPRY)

NasdaqGM · Biotechnology

6.32
+0.08 (+1.28%)
Updated Aug 18, 5:54 PM ET
AI Rating
Sell
Overall Score
35
Trend
25
Momentum
50
Risk
30

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Feb 24, 2026 120 sessions Aug 14, 2026

AI Analysis

ARS Pharmaceuticals, Inc. is trading at $6.32, up 1.28% on the session. The 50 day average sits at $7.57 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 38.4, which reads as weak, and MACD is bullish crossover. Volume is volume spike.

The nearest support is around $4.91 with resistance near $8.67, so that band frames the current range. Average daily movement is roughly $0.47, or about 7.5% of the share price, which is what any stop placement has to allow for. The overall health score of 35 out of 100 combines a trend score of 25, momentum of 50 and a risk score of 30.

Technical indicators

RSI (14)
38.4
weak
MACD
-0.443
bullish crossover
SMA 20
5.82
SMA 50
7.57
SMA 200
--
unknown
ATR (14)
0.47
avg daily range
Support
4.91
Resistance
8.67
Volume vs 20d
2.08x
volume spike
Volatility
76.3%
annualised
1 month
-24.26%
3 months
-28.84%

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.